Development of novel immunotherapy for malignant melanoma by targeting MDSC.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461682
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Dermatology
• Research Institution: Tohoku University
• Principal Investigator: Fujimura Taku 東北大学, 医学(系)研究科(研究院), 助教 (50396496)
• Co-Investigator(Kenkyū-buntansha): Aiba SETSUYA 東北大学, 医学系研究科, 教授 (80159269)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 腫瘍随伴マクロファージ / 制御性T細胞 / MDSC / 悪性黒色腫 / PD-L1 / ケモカイン

Outline of Final Research Achievements

Our present study revealed that, not only the expression of PD-L1, but also the production of chemokine is important to modify the immunosuppressive microenvironment in B16F10 melanoma model. In addition, on human M2 macrophages, the expression of PD-L1 could be decreased by the treatment of several immune therapy for metastatic melanoma. We published these data at Oncoimmunology in 2015. Moreover, we further investigated tumor-associated macrophages in the series of skin tumor, including invasive and non-invasive extramammary Paget's disease and mycosis fungicides. These data was published at Journal of Investigative Dermatology and Experimental Dermatology in 2015 and 2016.

Free Research Field

皮膚科